China Archives

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

22/04/2021 No Comments

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Investigation Report on China’s Hydroxychloroquine Market, 2021-2025

19/04/2021 No Comments

The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China’s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.

The Chloroquine Wars Part XV – How to Rig Research: Surgisphere Part II

15/04/2021 No Comments

It would be a historically amazing feat of maneuvering bureaucracy, worthy of its own epic book, movie, or perhaps a campfire song, to have wrangled that much data out of those hospitals with highly variable regulations and procedures, nearly all of which are in the U.S. healthcare system.

Hyperglycemia, hydroxychloroquine and the COVID‐19 pandemic

13/04/2021 No Comments

Hydroxychloroquine also can act as an oral hypoglycemic agent, as patients with diabetes taking hydroxychloroquine for rheumatologic diseases had a significant reduction in hemoglobin A1c when compared to methotrexate,40 and thus can serve to reduce hyperglycemia, a possible COVID‐19 risk factor for disease severity.

The Chloroquine Wars Part VIII – Hydroxychloroquine’s Safety Profile and a Cost-Benefit Analysis

31/03/2021 No Comments

While HCQ looks very safe overall for COVID-19 patients, it looks safest when used as a prophylactic or therapeutic for early stage COVID-19 patients, once again affirming the Primary HCQ Hypothesis as the strongest version of the HCQ Hypothesis.

The Chloroquine Wars Part II

03/03/2021 No Comments

On face, it certainly appears that complete silence in the public sphere about hydroxychloroquine’s potential was coordinated by powerful media forces.

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

28/01/2021 No Comments

Source: Reviews in Cardiovascular Medicine Peter A. McCullough, Paul E. Alexander, Robin Armstrong, Cristian Arvinte, Alan F. Bain, Richard P. Bartlett, Robert L. Berkowitz, Andrew

Ireland: Predictions of Global Hydroxychloroquine Market (2020 to 2027)

05/01/2021 No Comments

Hydroxychloroquine, an anti-malarial drug, when combined with chloroquine has the potential to be the major game-changer in medical history.

Yes, hydroxychloroquine is scientifically proven against COVID-19 – PART ONE

15/12/2020 No Comments

Source: Filipe Rafaeli Author: Filipe Rafaeli If you don’t want to die in this pandemic, read it to the end! Here I do a historical

A massive hydroxychloroquine meta-analysis (156 studies) has just been updated (version 28!).It says that HCQ works beyond all statistical doubt.

05/12/2020 No Comments

Source: HCQMeta.com HCQ is effective for COVID-19 when used early: meta-analysis of 156 studies (Version 28, December 4, 2020) • HCQ is effective for COVID-19.

HCQ is effective for COVID-19 when used early: analysis of 132 studies

02/11/2020 No Comments

Source: HCQmeta.com • HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 132 studies to date is

China approves chloroquine (instead of hydroxychloroquine) against covid-19

21/08/2020 No Comments

Source: Archyde China has included chloroquine in guidelines for treating Covid-19 patients. While Remdesivir, an antiviral approved by the United States, Europe and Hong Kong, is not on

CCP leaders are secretly taking Hydroxychloroquine to prevent COVID-19

17/08/2020 No Comments

Source: The Epoch Times On July 31, the China Central Television attacked the role of Hydroxychloroquine as treatment against the CCP Virus, and labeled President

China Study of 2882 patients: Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

03/08/2020 No Comments

HCQ treatment can reduce systemic inflammation and inhibit the cytokine storm, thus protecting multiple organs from inflammatory injuries.

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

03/08/2020 No Comments

Source: Springer Link Dear Editor, The coronavirus disease 2019 (COVID-19) pandemic caused by widespread infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Chen

Countries using hydroxychloroquine have low coronavirus fatality rate compared to countries that don’t, Association of American Physicians and Surgeons says

23/07/2020 No Comments

The report was based on observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically.

Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus

22/06/2020 No Comments

Source: BioRxiv The pandemic coronavirus COVID-19 affected global health from the end of 2019 to 2020 and may challenge global health in the future. There

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

22/06/2020 No Comments

This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

15/05/2020 No Comments

Source: Springer Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments.

Study of the safety and efficacy of chloroquine for the treatment of COVID-19

04/05/2020 No Comments

Source: MedRxiv Background Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in vitro. In

China: Study re-affirms hydroxychloroquine useful in decreasing Covid deaths

02/05/2020 No Comments

Source: India Today As some Western studies found hydroxychloroquine ineffective as a potential Covid-19 therapy, a new Chinese research has reported that the anti-malarial drug

China study of 568 critically ill Covid-19 patients: Hydroxychloroquine treatment significantly associated with a decreased mortality, through attenuation of inflammatory cytokine storm.

01/05/2020 No Comments

Source: MedRxiv Abstract Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high mortality. The most urgent thing is to find

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19

27/04/2020 No Comments

Source: MedRxiv Importance: Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high mortality. The most urgent thing is to find effective

Wuhan, China: Hydroxychloroquine Clinical Benefits Become Clearer

05/04/2020 No Comments

Hydroxychloroquine reduces time to clinical recovery when treating COVID-19 disease patients: The accelerating debate about the clinical benefit of treating COVID-19 disease patients with hydroxychloroquine

Hydroxychloroquine can shorten time to recovery in COVID-19: study

22/03/2020 No Comments

Zhaowei Chen, from the Renmin Hospital of Wuhan University in China, and colleagues examined the efficacy of HCQ in treatment of COVID-19. Sixty-two patients with COVID-19 diagnosed

China: Wuhan clinical trial, use of HCQ significantly shortens TTCR and promotes absorption of pneumonia

22/03/2020 No Comments

Source medRxiv Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Zhaowei Chen, View ORCID ProfileJijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, View ORCID ProfileZhan Zhangdoi: https://doi.org/10.1101/2020.03.22.20040758This article is a preprint and

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

09/03/2020 No Comments

An initial Chinese study, published in Clinical Infectious Diseases: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently

HIBISCUS: Hydroxychloroquine for the Secondary Prevention of Thrombotic and Obstetrical Events in Primary Antiphospholipid Syndrome

17/12/2018 No Comments

Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16].

The Palmer Foundation

Category: China

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

Investigation Report on China’s Hydroxychloroquine Market, 2021-2025

The Chloroquine Wars Part XV – How to Rig Research: Surgisphere Part II

Hyperglycemia, hydroxychloroquine and the COVID‐19 pandemic

The Chloroquine Wars Part VIII – Hydroxychloroquine’s Safety Profile and a Cost-Benefit Analysis

The Chloroquine Wars Part II

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19 infection includes HCQ & Ivermectin

Ireland: Predictions of Global Hydroxychloroquine Market (2020 to 2027)

Yes, hydroxychloroquine is scientifically proven against COVID-19 – PART ONE

A massive hydroxychloroquine meta-analysis (156 studies) has just been updated (version 28!).It says that HCQ works beyond all statistical doubt.

HCQ is effective for COVID-19 when used early: analysis of 132 studies

China approves chloroquine (instead of hydroxychloroquine) against covid-19

CCP leaders are secretly taking Hydroxychloroquine to prevent COVID-19

China Study of 2882 patients: Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

Countries using hydroxychloroquine have low coronavirus fatality rate compared to countries that don’t, Association of American Physicians and Surgeons says

Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

Study of the safety and efficacy of chloroquine for the treatment of COVID-19

China: Study re-affirms hydroxychloroquine useful in decreasing Covid deaths

China study of 568 critically ill Covid-19 patients: Hydroxychloroquine treatment significantly associated with a decreased mortality, through attenuation of inflammatory cytokine storm.

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19

Wuhan, China: Hydroxychloroquine Clinical Benefits Become Clearer

Hydroxychloroquine can shorten time to recovery in COVID-19: study

China: Wuhan clinical trial, use of HCQ significantly shortens TTCR and promotes absorption of pneumonia

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

HIBISCUS: Hydroxychloroquine for the Secondary Prevention of Thrombotic and Obstetrical Events in Primary Antiphospholipid Syndrome

Copyright 2020 © The Palmer Foundation